Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Alethia Biotherapeutics Ulc is active in the Biotechnology & Pharmaceuticals technology area, where it currently has 1 pending office action. This 1 action is assigned to 1 distinct examiner, indicating a specific prosecution focus. The work is being conducted within 1 distinct art unit, suggesting a specialized area of biological or pharmaceutical research.
The busiest examiner for this portfolio is LUNDE, GRACE HENRY, who is managing 1 busiest examiner pending office action. Because there is 1 distinct examiner for the company, LUNDE, GRACE HENRY is the examiner currently reviewing their pending matters. This 1 pending office action is the only active case reported for the company at this time.
Practitioners can concentrate their efforts on the 1 distinct art unit and the specific requirements of LUNDE, GRACE HENRY. With only 1 pending office action, the immediate progress of the Biotechnology & Pharmaceuticals portfolio depends on this 1 interaction. The 1 busiest examiner pending action represents the entirety of the current administrative process for Alethia Biotherapeutics Ulc.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LUNDE, GRACE HENRY | 1 | 63.0% | +38.9% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18287327 | METHOD FOR ALLOWING IMMUNE CELLS INFILTRATION IN TUMORS | LUNDE, GRACE HENRY | — |
| Art Unit | Apps |
|---|---|
| 1641 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18287327 | METHOD FOR ALLOWING IMMUNE CELLS INFILTRATION IN TUMORS | LUNDE, GRACE HENRY | 1641 | §102§103§112DP | Non-Final OA | — | Pending | Oct 18, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial